ClinicalTrials.gg
RecruitingNCT06136624OMAHA-003Updated Nov 13, 2026

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

A Phase 3 interventional study of Opevesostat and Abiraterone acetate in Prostate Cancer Metastatic, sponsored by Merck Sharp & Dohme LLC. Recruiting at 288 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.
Updated Nov 13, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Prostatic Neoplasms by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms · Merck & Co., Inc.

Planned enrollment
4th of 22
1,310 · median 93
Started
2023
with 2 others
Phase 3
9 of 22
3 open now
Registered
16th of 22
by date

Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 22 studies in Prostatic Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has - or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
  • Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
  • Has current evidence of distant disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
  • Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
  • Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
  • Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM)
  • Has provided tumor tissue from a fresh core or excisional from soft tissue not previously irradiated
  • Has an (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
  • Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
  • Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment
  • Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment
  • If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression >4 weeks since the last flutamide treatment and >6 weeks since the last bicalutamide or nilutamide treatment
  • Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization
  • Participants with (HIV) infection must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable at Screening.
  • Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom

Exclusion criteria

Exclusion Criteria:

  • Has a gastrointestinal disorder that might affect absorption
  • Has a history of pituitary dysfunction
  • Has poorly controlled diabetes mellitus
  • Has abnormal serum potassium or sodium level
  • Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
  • Has a history of seizure within 6 months of providing documented or any condition that may predispose to seizures within 12 months before the date of randomization
  • Has a history of clinically significant ventricular arrhythmias
  • Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization
  • Has undergone major surgery, including local prostate intervention (except prostate ), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications
  • Participants who have not adequately recovered from major surgery or have ongoing surgical complications
  • Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization
  • Has received radium-223 or Lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or Lutetium-177 administered more than 4 weeks before the date of randomization
  • Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization
  • Has received colony-stimulating factors within 28 days before the date of randomization
  • Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and transfusions are acceptable if not given within 28 days of the date of randomization
  • Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks
  • Has a "superscan" bone scan
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study medication
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in past 2 years
  • Has an active infection requiring systemic therapy
  • Has concurrent active or known active infection
  • Has a history of long syndrome
  • Has any of the following at Screening Visit: hypotension (systolic BP \<110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy)
  • Is unable to swallow capsules/tablets
  • Is currently being treated with cytochrome 450-inducing antiepileptic drugs for seizures
  • Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention
  • Received prior systemic anticancer therapy including agents within 4 weeks before the first dose of study intervention
  • Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
  • Received a live or within 30 days before the first dose of study intervention
  • Systemic use of the following medications within 2 weeks before the first dose of study intervention: strong inducers (eg, avasimibe, carbamazepine, lumacaftor, phenobarbital, rifampicin, rifapentine, or St John's Wort); P-gp inhibitors (eg, erythromycin, clarithromycin, rifampicin, ketoconazole, itraconazole, posaconazole, artesunate-pyronaridine, ritonavir, indinavir, nelfinavir, atazanavir, glecaprevir-pibrentasvir, simeprevir, ledipasvir-sofosbuvir, verapamil, diltiazem, dronedarone, propafenone, quinidine, cyclosporine, valspodar, or milk thistle [Silybum marianum])
  • Use of aldosterone antagonist (eg, spironolactone, eplerenone) and phenytoin within 4 weeks before the start of the study intervention
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,310 participants (estimated)

Study arms

  • Experimental
    Opevesostat

    Participants receive opevesostat 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) dose will also be provided to participants for use as rescue medication. Prior to study protocol amendment 9, prednisone was provided as a rescue medication during adrenal recovery, titrated at 5mg daily maintenance dose and then titrated to discontinuation.

    Drug: Opevesostat · Drug: Hydrocortisone · Drug: Fludrocortisone acetate · Drug: Prednisone · Drug: Dexamethasone

  • Active comparator
    Abiraterone Acetate or Enzalutamide

    Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets.

    Drug: Abiraterone acetate · Drug: Enzalutamide · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants

    OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-positive participants will be reported for each study arm.

    Time frame: Up to ~54 months

  2. OS in AR LBD Mutation-Negative Participants

    OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-negative participants will be reported for each study arm.

    Time frame: Up to ~54 months

Secondary outcomes

  1. Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review in AR LBD Mutation-Positive Participants

    rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm.

    Time frame: Up to ~36 months

  2. rPFS Per Prostate Cancer Working Group-modifiedRECIST 1.1 as Assessed by Blinded Independent Central Review in AR LBD Mutation-Negative Participants

    rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm.

    Time frame: Up to ~36 months

  3. Time to Initiation of the First Subsequent Anti-Cancer Therapy or Death (TFST)

    TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first.

    Time frame: Up to ~54 months

  4. Objective Response (OR)

    OR is determined by PCWG-modified RECIST 1.1 as assessed by BICR.

    Time frame: Up to ~54 months

  5. Duration of Response (DOR)

    DOR is determined by PCWG-modified RECIST 1.1 as assessed by BICR.

    Time frame: Up to ~54 months

  6. Time to Pain Progression (TTPP)

    TTPP is assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and opiate analgesic use (Analgesic Quantification Algorithm \[AQA\] Score).

    Time frame: Up to ~54 months

  7. Time to Prostate-specific Antigen (PSA) Progression

    The time from randomization to PSA progression. The PSA progression date is defined as the date of either: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.

    Time frame: Up to ~54 months

  8. Time to First Symptomatic Skeletal-related Event (SSRE)

    The time from randomization to the first occurrence of any of the following symptomatic skeletal-related events: 1) Use of EBRT to prevent or relieve skeletal symptoms; 2) new symptomatic pathologic bone fracture (vertebral or non-vertebral); 3) spinal cord compression; or 4) tumor-related orthopedic surgical intervention.

    Time frame: Up to ~54 months

  9. Number of Participants Who Experience an Adverse Event

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~54 months

  10. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~54 months

07

Study locations

236 of 288 sites recruiting
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)
    Orange, California 92868, United States
    Completed

    Not enrolling at this site — choose another above.

  • Stanford Cancer Center ( Site 0036)
    Palo Alto, California 94304, United States
    Recruiting
    • Study Coordinator · Contact650-725-2078
  • Kaiser Permanente Riverside Medical Center ( Site 0099)
    Riverside, California 92505, United States
    Recruiting
    • Study Coordinator · Contact951-809-8361
  • Anschutz Cancer Pavilion ( Site 0046)
    Aurora, Colorado 80045, United States
    Recruiting
    • Study Coordinator · Contact302-290-3598
  • University of Colorado Health - Highlands Ranch Hospital ( Site 0111)
    Highlands Ranch, Colorado 80129, United States
    Recruiting
    • Study Coordinator · Contact302-290-3598
  • Colorado Clinical Research ( Site 0067)
    Lakewood, Colorado 80228, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Colorado Health - Lone Tree Medical Center ( Site 0112)
    Lone Tree, Colorado 80124, United States
    Recruiting
    • Study Coordinator · Contact720-848-5146
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
    New Haven, Connecticut 06510, United States
    Recruiting
    • Study Coordinator · Contact203-737-8076
  • Florida Cancer Specialists - South ( Site 7003)
    Fort Myers, Florida 33901, United States
    Completed

    Not enrolling at this site — choose another above.

  • Bruce W. Carter Veterans Affairs Medical Center ( Site 0082)
    Miami, Florida 33125, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051)
    Miami, Florida 33136, United States
    Recruiting
    • Study Coordinator · Contact305-243-1543
  • University of Illinois at Chicago ( Site 0105)
    Chicago, Illinois 60612, United States
    Recruiting
    • Study Coordinator · Contact973-330-2391
  • University of Chicago Medical Center ( Site 0045)
    Chicago, Illinois 60637, United States
    Recruiting
    • Study Coordinator · Contact773-702-7609
  • University of Iowa ( Site 0047)
    Iowa City, Iowa 52242, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Kentucky Chandler Medical Center ( Site 0048)
    Lexington, Kentucky 40536, United States
    Completed

    Not enrolling at this site — choose another above.

  • Ochsner Clinic Foundation ( Site 0108)
    New Orleans, Louisiana 70121, United States
    Completed

    Not enrolling at this site — choose another above.

  • Baltimore Veterans Affairs Medical Center ( Site 0069)
    Baltimore, Maryland 21201, United States
    Recruiting
    • Study Coordinator · Contact410-707-4011
  • Greenebaum Comprehensive Cancer Center ( Site 0049)
    Baltimore, Maryland 21201, United States
    Recruiting
    • Study Coordinator · Contact410-707-4011
  • Henry Ford Hospital ( Site 0015)
    Detroit, Michigan 48202, United States
    Completed

    Not enrolling at this site — choose another above.

  • Avera Cancer Institute - Marshall ( Site 0122)
    Marshall, Minnesota 56258, United States
    Recruiting
    • Study Coordinator · Contact605-601-1830
  • M Health Fairview Clinics and Surgery Center ( Site 0019)
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Study Coordinator · Contact612-626-1422
  • Metro-Minnesota Community Clinical Oncology ( Site 0014)
    Saint Louis Park, Minnesota 55416, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hattiesburg Clinic Hematology/Oncology ( Site 0120)
    Hattiesburg, Mississippi 39401, United States
    Recruiting
    • Study Coordinator · Contact601-261-1700
  • Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062)
    St Louis, Missouri 63110, United States
    Recruiting
    • Study Coordinator · Contact314-286-2341
  • University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095)
    Omaha, Nebraska 68105, United States
    Recruiting
    • Study Coordinator · Contact402-559-8500
  • Comprehensive Cancer Centers of Nevada ( Site 0010)
    Las Vegas, Nevada 89148, United States
    Recruiting
    • Study Coordinator · Contact702-952-1251
  • Atlantic Health System Morristown Medical Center ( Site 0115)
    Morristown, New Jersey 07960, United States
    Recruiting
    • Study Coordinator · Contact973-971-7960
  • Rutgers Cancer Institute of New Jersey ( Site 0033)
    New Brunswick, New Jersey 08903, United States
    Completed

    Not enrolling at this site — choose another above.

  • James J. Peters VA Medical Center ( Site 0088)
    The Bronx, New York 10468, United States
    Recruiting
    • Study Coordinator · Contact718-584-9000
  • University Hospitals Cleveland Medical Center ( Site 0043)
    Cleveland, Ohio 44106, United States
    Recruiting
    • Study Coordinator · Contact216-844-3951
  • Oregon Health and Science University ( Site 0028)
    Portland, Oregon 97239, United States
    Completed

    Not enrolling at this site — choose another above.

  • VA Portland Health Care System ( Site 0058)
    Portland, Oregon 97239, United States
    Recruiting
    • Study Coordinator · Contact503-220-8262
  • AHN Allegheny General Hospital ( Site 0001)
    Pittsburgh, Pennsylvania 15212, United States
    Completed

    Not enrolling at this site — choose another above.

  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083)
    Charleston, South Carolina 29401, United States
    Completed

    Not enrolling at this site — choose another above.

  • Avera Cancer Institute - Aberdeen ( Site 0123)
    Aberdeen, South Dakota 57401, United States
    Recruiting
    • Study Coordinator · Contact605-601-1830
  • Avera Cancer Institute - Mitchell ( Site 0121)
    Mitchell, South Dakota 57301, United States
    Recruiting
    • Study Coordinator · Contact605-601-1830
  • Avera Cancer Institute - Pierre ( Site 0118)
    Pierre, South Dakota 57501, United States
    Recruiting
    • Study Coordinator · Contact605-224-3370
  • Avera Cancer Institute- Research ( Site 0094)
    Sioux Falls, South Dakota 57105, United States
    Recruiting
    • Study Coordinator · Contact605-322-6900
  • Avera Cancer Institute - Yankton ( Site 0117)
    Yankton, South Dakota 57078, United States
    Recruiting
    • Study Coordinator · Contact605-655-1800
  • SCRI Oncology Partners ( Site 7000)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact615-218-4647
  • Texas Oncology - Central/South Texas ( Site 8003)
    Austin, Texas 78731, United States
    Recruiting
    • Study Coordinator · Contact512-427-9400
  • Texas Oncology - DFW ( Site 8001)
    Dallas, Texas 75246, United States
    Completed

    Not enrolling at this site — choose another above.

  • Texas Oncology - Gulf Coast ( Site 8002)
    Houston, Texas 77024, United States
    Recruiting
    • Study Coordinator · Contact713-467-1722
  • University of Virginia Health System ( Site 0054)
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Study Coordinator · Contact434-327-3029
  • VCU Health Adult Outpatient Pavillion ( Site 0061)
    Richmond, Virginia 23219, United States
    Completed

    Not enrolling at this site — choose another above.

  • Blue Ridge Cancer Care ( Site 0004)
    Roanoke, Virginia 24014, United States
    Recruiting
    • Study Coordinator · Contact540-982-0237
  • Fred Hutchinson Cancer Center ( Site 0013)
    Seattle, Washington 98109, United States
    Recruiting
    • Study Coordinator · Contact617-413-9079
  • Medical College of Wisconsin ( Site 0020)
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Study Coordinator · Contact414-805-4600
  • Hospital Británico de Buenos Aires-Oncology ( Site 0202)
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1280AEB, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205)
    Buenos Aires, Buenos Aires F.D. C1419AHN, Argentina
    Recruiting
    • Study Coordinator · Contact+5491145744343
  • Instituto Alexander Fleming-Alexander Fleming ( Site 0206)
    Buenos Aires, Buenos Aires F.D. C1426ANZ, Argentina
    Recruiting
    • Study Coordinator · Contact+5491132218900
  • Sanatorio Parque ( Site 0208)
    Rosario, Santa Fe Province S2000DSV, Argentina
    Recruiting
    • Study Coordinator · Contact+5493414200222
  • Hospital Aleman-Oncology ( Site 0207)
    Buenos Aires, C1118AAT, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204)
    Mendoza, M5500AYB, Argentina
    Recruiting
    • Study Coordinator · Contact+5492615449901
  • Dubbo Hospital ( Site 0235)
    Dubbo, New South Wales 2830, Australia
    Recruiting
    • Study Coordinator · Contact0268096200
  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0234)
    Macquarie University, New South Wales 2109, Australia
    Recruiting
    • Study Coordinator · Contact0298122979
  • Westmead Hospital ( Site 0232)
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Study Coordinator · Contact+61288905555
  • Princess Alexandra Hospital-Cancer Care Serices ( Site 0237)
    Brisbane, Queensland 4102, Australia
    Recruiting
    • Study Coordinator · Contact+6173176 9289
  • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230)
    Melbourne, Victoria 3000, Australia
    Recruiting
    • Study Coordinator · Contact03 8559 5000
  • Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280)
    Graz, Styria 8036, Austria
    Recruiting
    • Study Coordinator · Contact+4331638581307
  • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276)
    Linz, Upper Austria 4020, Austria
    Recruiting
    • Study Coordinator · Contact+4373276774724
  • Klinikum Wels-Grieskirchen GmbH ( Site 0279)
    Wels, Upper Austria 4600, Austria
    Recruiting
    • Study Coordinator · Contact+4372424152328
  • Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320)
    Vitória, Espírito Santo 29041-295, Brazil
    Recruiting
    • Study Coordinator · Contact+55 27 3334-8346
  • Obras Sociais Irma Dulce ( Site 0302)
    Salvador, Estado de Bahia 41680-430, Brazil
    Recruiting
    • Study Coordinator · Contact+55 71 3310-1978
  • Hospital Felicio Rocho ( Site 0317)
    Belo Horizonte, Minas Gerais 30110-934, Brazil
    Recruiting
    • Study Coordinator · Contact+55 31 35147195
  • Hospital Mario Penna ( Site 0309)
    Belo Horizonte, Minas Gerais 30380-472, Brazil
    Recruiting
    • Study Coordinator · Contact+551 31 3299-9543
  • Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314)
    Curitiba, Paraná 80440-220, Brazil
    Recruiting
    • Study Coordinator · Contact5541991681411
  • Clínica de Neoplasias Litoral ( Site 0305)
    Itajaí, Santa Catarina 88301-220, Brazil
    Recruiting
    • Study Coordinator · Contact+5547984046243
  • Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308)
    Bragança Paulista, São Paulo 12916-542, Brazil
    Recruiting
    • Study Coordinator · Contact+55 11 98337-1381
  • A. C. Camargo Cancer Center ( Site 0310)
    São Paulo, São Paulo 01509-010, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cross Cancer Institute ( Site 0332)
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
    • Study Coordinator · Contact7804328762
  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336)
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Study Coordinator · Contact613-737-7700
  • Sunnybrook Research Institute ( Site 0331)
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Study Coordinator · Contact647-533-1023
  • Princess Margaret Cancer Centre ( Site 0330)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact(416) 946-4501
  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328)
    Greenfield Park, Quebec J4V 2H1, Canada
    Recruiting
    • Study Coordinator · Contact4504665000 ext 3226
  • Centre Hospitalier de l'Université de Montréal ( Site 0326)
    Montreal, Quebec H2X 3E4, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327)
    Québec, Quebec G1J 1Z4, Canada
    Recruiting
    • Study Coordinator · Contact418 525-4444
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329)
    Sherbrooke, Quebec J1H 5H4, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IC La Serena Research ( Site 0356)
    La Serena, Coquimbo Region 1720430, Chile
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Research Chile SpA ( Site 0358)
    Valdivia, Los Ríos Region 5110683, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinica Universidad Catolica del Maule-Oncology ( Site 0355)
    Talca, Maule Region 3465584, Chile
    Recruiting
    • Study Coordinator · Contact+56947532700
  • Fundación Arturo López Pérez ( Site 0353)
    Santiago, Region M. de Santiago 7500921, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354)
    Santiago, Region M. de Santiago 8330024, Chile
    Recruiting
    • Study Coordinator · Contact+56934331806
  • Bradfordhill-Clinical Area ( Site 0351)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • Bradford Hill Norte ( Site 0357)
    Antofagasta, 1240000, Chile
    Recruiting
    • Study Coordinator · Contact56442023631
  • Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408)
    Hefei, Anhui 230000, China
    Recruiting
    • Study Coordinator · Contact+86 02782201756
  • Peking University First Hospital-Urology ( Site 0390)
    Beijing, Beijing Municipality 100034, China
    Recruiting
    • Study Coordinator · Contact+86 (010) 64008229
  • Beijing Friendship Hospital Affiliate of Capital University ( Site 0396)
    Beijing, Beijing Municipality 100050, China
    Recruiting
    • Study Coordinator · Contact+86(010)63138375
  • Beijing Cancer hospital-Urinary Surgery ( Site 0395)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact86 010 8812 1122
  • The First Affiliated Hospital of Chongqing Medical University ( Site 0427)
    Chongqing, Chongqing Municipality 400010, China
    Recruiting
    • Study Coordinator · Contact023 89012012
  • Chongqing University Cancer Hospital ( Site 0416)
    Chongqing, Chongqing Municipality 400030, China
    Recruiting
    • Study Coordinator · Contact02365075629
  • Southwest Hospital of Third Military Medical University ( Site 0420)
    Chongqing, Chongqing Municipality 400038, China
    Recruiting
    • Study Coordinator · Contact023 68765878
  • Chongqing Three Gorges Central Hospital's ( Site 0426)
    Chongqing, Chongqing Municipality 404100, China
    Recruiting
    • Study Coordinator · Contact023 58103150
  • The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414)
    Fuzhou, Fujian 350005, China
    Recruiting
    • Study Coordinator · Contact+86059187983333
  • The First Affiliated hospital of Xiamen University-Urology ( Site 0415)
    Xiamen, Fujian 361003, China
    Recruiting
    • Study Coordinator · Contact0592-2132222
  • The First Affiliated Hospital of Guangzhou Medical University ( Site 0412)
    Guangzhou, Guangdong 510230, China
    Recruiting
    • Study Coordinator · Contact+8602034294311
  • Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413)
    Guangzhou, Guangdong 511400, China
    Recruiting
    • Study Coordinator · Contact+8602087343533
  • Tongji Hospital Tongji Medical,Science & Technology ( Site 0407)
    Wuhan, Hubei 430000, China
    Recruiting
    • Study Coordinator · Contact027-83665555
  • Hubei Cancer Hospital-Urinary surgery ( Site 0406)
    Wuhan, Hubei 430079, China
    Recruiting
    • Study Coordinator · Contact8613907110640

Showing the first 100 of 288 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Yu EY, Gratzke C, Burotto M, Zhang AY, Levesque E, Ortega F, Peer A, Vile D, Chen ZH, Song Y, Schloss C, Todoric J, Garratt C, Poehlein C, Antonarakis ES, Fizazi K. Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. Future Oncol. 2026 Mar;22(7):765-772. doi: 10.1080/14796694.2025.2595914. Epub 2026 Feb 23. PubMed 41732008 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2028, 58 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 58 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Aug 2028 → Nov 2028 and completion Feb 2030 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Dec 31, 2023
Primary completionEst.
Nov 30, 2028was Aug 2028
CompletionEst.
Mar 29, 2030was Feb 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. 4 sites changed recruiting status (2 now active, not recruiting, 1 now completed, …)
Show 4 sites
  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) · Prague, CzechiaRecruiting→Active, not recruiting
  • IC La Serena Research ( Site 0356) · La Serena, ChileActive, not recruiting→Completed
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1302) · Bydgoszcz, PolandRecruiting→Active, not recruiting
  • Ad-Vance Medical Research-Research ( Site 1353) · Ponce, Puerto RicoActive, not recruiting→Recruiting
Show 2 added (1 Chile, 1 Czechia)
  • Fundación Arturo López Pérez ( Site 0353) · Santiago, Chile
  • Fakultní nemocnice Motol a Homolka ( Site 0551) · Prague, Czechia
Show 2 removed
  • FALP ( Site 0353) · Santiago, Chile
  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) · Prague, Czechia
across 4 updates, Oct 6, 2026 – Nov 13, 2026
Primary completion
Aug 2, 2028→Nov 30, 2028
Nov 5, 2026
Study completion
Feb 15, 2030→Mar 29, 2030
Nov 5, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) · Prague, CzechiaContact removed •••6410
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1302) · Bydgoszcz, PolandContact removed •••3589
  • Ad-Vance Medical Research-Research ( Site 1353) · Ponce, Puerto RicoContact added •••6697
across 3 updates, Oct 6, 2026 – Nov 13, 2026
Show all 4 updates
  1. Nov 13, 2026
    Ad-Vance Medical Research-Research ( Site 1353) is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ad-Vance Medical Research-Research ( Site 1353) · Ponce, Puerto RicoContact added •••6697
  2. Nov 5, 2026
    1 site added, 1 site removed. Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1302) is now Active, not recruiting
    Show site
    • Fakultní nemocnice Motol a Homolka ( Site 0551) · Prague, Czechia
    Show 1 removed
    • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) · Prague, Czechia
    Primary completion Aug 2, 2028→Nov 30, 2028
    Study completion Feb 15, 2030→Mar 29, 2030
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1302) · Bydgoszcz, PolandContact removed •••3589
    + 1 other change: verification date
  3. Nov 3, 2026
    IC La Serena Research ( Site 0356) is now Completed
    + 1 other change: references
  4. Oct 6, 2026
    1 site added, 1 site removed. Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) is now Active, not recruiting
    Show site
    • Fundación Arturo López Pérez ( Site 0353) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0353) · Santiago, Chile
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) · Prague, CzechiaContact removed •••6410
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06136624
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 31, 2023
Primary completion
Nov 30, 2028 (estimated)
Completion
Mar 29, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opevesostat

Start the discussion